Recommendations on use of antivirals
| Guideline | Country | Year | Antivirals | Indications |
| China (MoH)54 | China | 2003 | NS | NA |
| Dermatology Advisor47 | Global | 2017 | Cidofovir | For severe cases only, due to risk of nephrotoxicity |
| DermNet48 | Global | 2014 | Cidofovir | Severe cases |
| ECDC56 | Europe | 2019 | NS | NS |
| eMedicine49 | Global | 2020 | Cidofovir | Severe life threatening cases |
| Ireland HPSC53 | Ireland | 2021 | NS | NS |
| Medscape51 | Global | 2019 | Cidofovir | NS |
| NCDC44 | Nigeria | 2019 | NS | NA |
| PHE/UKHSA52 | England | 2019 | Cidofovir, tecovirimat | NS |
| Singapore FETP46 | Singapore | 2020 | NS | NS |
| Taiwan CDC45 | Taiwan | 2009 | NS | NS |
| UpToDate50 | Global | 2021 | Cidofovir, tecovirimat | Cidofovir: risk of nephrotoxicity |
| US CDC55 | USA | 2018 | Cidofovir, brincidofovir, tecovirimat | Consider cidofovir and brincidofovir in severe cases |
| WHO18 | Global | 2019 | Tecovirimat | Only as part of clinical research |
An overview of the antiviral treatments recommended to consider in monkeypox. None of the guidelines provided further indications to guide optimal timing, dose or duration of treatment.
CDC, Centres for Disease Control; ECDC, European Centre for Disease Control and Prevention; EMA, the European Medicines Agency; FETP, Singapore Field Epidemiology Training Programme; HPSC, Health Protection Surveillance Centre; MoH, Ministry of Health; NCDC, Nigeria Centre for Disease Control; NS, not stated; PHE, Public Health England; UKHSA, UK Health Security Agency.